Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. (4th July 2021)

• Record Type: Journal Article
• Authors: Fargnoli, M. C.; Esposito, M.; Ferrucci, S.; Girolomoni, G.; Offidani, A.; Patrizi, A.; Peris, K.; Costanzo, A.; Malara, G.; Pellacani, G.; Romanelli, M.; Amerio, P.; Cristaudo, A.; Flori, M. L.; Motolese, A.; Betto, P.; Patruno, C.; Pigatto, P.; Sirna, R.; Stinco, G.; Zalaudek, I.; Bianchi, L.; Boccaletti, V.; Cannavò, S. P.; Cusano, F.; Lembo, S.; Mozzillo, R.; Gallo, R.; Potenza, C.; Rongioletti, F.; Tiberio, R.; Grieco, T.; Micali, G.; Persechino, S.; Pettinato, M.; Pucci, S.; Savi, E.; Stingeni, L.; Romano, A.; Argenziano, G.;
• Is Part Of: Journal of dermatological treatment. Volume 32:Number 5(2021)
• Page Start: 507
• Page End: 513
• Publication Date: 2021-07-04
• Subjects: Atopic dermatitis -- dupilumab -- real-life; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2019.1682503
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.